J&J | JNJ - Interest Income



J&J reported 332M in Interest Income for its fiscal quarter ending in March of 2025.


Interest Income Change Date
AbbVie USD 73M 19M Mar/2025
Abbott USD 71M 11M Jun/2025
AstraZeneca 68M 16M Jun/2025
Baxter International USD 17M 7M Mar/2025
Bayer 92M 22M Mar/2025
Becton, Dickinson and Co. USD 5M 0 Jun/2025
Biogen USD 32.3M 8.4M Jun/2025
Boston Scientific USD 4M 3M Dec/2022
Dexcom 28M 500K Jun/2025
Edwards Lifesciences USD 64M 64M Dec/2024
Eli Lilly USD 40M 8.3M Jun/2025
Gilead Sciences 73M 21M Jun/2025
GlaxoSmithKline 50M 4M Jun/2025
Globus Medical USD 815K 3.08M Dec/2024
Hologic USD 16.4M 1.5M Jun/2025
Insulet USD 10.1M 200K Jun/2025
Integra LifeSciences USD 4.71M 290K Jun/2025
Intuitive Surgical 88.7M 1.7M Jun/2025
J&J 332M 51M Mar/2025
Medtronic USD 114M 23M Jan/2025
Merck USD 109M 37M Mar/2025
Merit Medical Systems USD 3.76M 29K Jun/2025
Pfizer USD 156M 13M Jun/2025
Regeneron Pharmaceuticals 174.8M 1.3M Jun/2025
Roche Holding 2M 12M Dec/2020
Sanofi 76M 10M Jun/2025
Stryker USD 38M 9M Mar/2025
Tandem Diabetes Care USD 4.19M 318K Mar/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025
Zoetis 19M 4M Jun/2025